Drug Trial Radar · NCT01307397
A Study of Vemurafenib in Participants With Metastatic Melanoma
Last checked: Nov 20, 2026Latest source record: Dec 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,219
Actual
Start
Mar 1, 2011
Primary completion
Feb 24, 2016
Study completion Feb 24, 2016
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Mar 2, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multi-center study evaluates the safety and efficacy of vemurafenib in participants with BRAF V600 mutation-positive, surgically incurable, and unresectable Stage IIIC or IV (American Joint Committee on Cancer \[AJCC\]) metastatic melanoma.
Conditions
- Malignant Melanoma
Interventions
VemurafenibDrug
Participants will receive continuous oral doses of vemurafenib 960 mg (four 240 mg tablets) twice daily in each 28-day treatment cycle until the development of progressive disease, unacceptable toxicity, consent withdrawal, protocol violations endangering participant's safety, death, or study termination by the Sponsor, whichever occurs first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing Any Grade 3 or 4 Adverse Events (AEs) as Determined by National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version 4.0Time frame: Baseline up to 28 days post end of treatment (maximum up to 46 months)
- Percentage of Participants With at Least 1 AE Leading to Study Drug Interruption or Drug DiscontinuationTime frame: Baseline up to 28 days post end of treatment (maximum up to 46 months)
- Percentage of Participants With AEs of Special InterestTime frame: Baseline up to 28 days post end of treatment (maximum up to 46 months)
- Mean Cumulative Dose of VemurafenibTime frame: Baseline up to end of treatment or death (maximum up to 46 months)
- Duration of Vemurafenib TreatmentTime frame: Baseline up to end of treatment or death (maximum upto 46 months)
- Mean Total Vemurafenib Dose Per DayTime frame: Baseline up to end of treatment or death (maximum up to 46 months)
- Dose Intensity of VemurafenibTime frame: Baseline up to end of treatment or death (maximum upto 46 months)
Locations
280 sites in 44 countries. Site status is shown where the registry gives one.
University "Mother Theresa" Hospital Center; Oncology Department
Tirana, Albania
Hospital Britanico; Oncologia
Buenos Aires, Argentina
Fundación CIDEA
Buenos Aires, Argentina
Inst. Alexander Fleming; Oncologia
Buenos Aires, Argentina
Melanoma Institute Australia
North Sydney, New South Wales, Australia
Newcastle Mater Misericordiae Hospital; Oncology
Waratah, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Border Medical Oncology
Wodonga, New South Wales, Australia
Greenslopes Private Hospital; Gallipoli Research Centre
Greenslopes, Queensland, Australia
The Townsville Hospital; Townsville Cancer Centre
Townsville, Queensland, Australia
Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology
Woolloongabba, Queensland, Australia
Royal Adelaide Hospital; Oncology
Adelaide, South Australia, Australia
Geelong Hospital; Geelong Cardiology Practice
Geelong, Victoria, Australia
Peter MacCallum Cancer Centre; Medical Oncology
Melbourne, Victoria, Australia
Alfred Hospital
Melbourne, Victoria, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
Landeskrankenhaus Feldkirch; Abteilung für Innere Medizin
Feldkirch, Austria
LKH Graz; Abteilung für allgemeine Dermatologie
Graz, Austria
LKH Innsbruck; Universitätsklinik für Dermatologie
Innsbruck, Austria
Krankenhaus der Elisabethinen Linz; Abteilung für Dermatologie
Linz, Austria
Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
Salzburg, Austria
LKH Salzburg; Universitätsklinik für Dermatologie
Salzburg, Austria
Landesklinikum St. Pölten
Sankt Pölten, Austria
Medizinische Universität Wien; Univ.Klinik für Dermatologie
Vienna, Austria
UZ Brussel
Brussels, Belgium
Cliniques Universitaires St-Luc
Brussels, Belgium
Sint Augustinus Wilrijk
Wilrijk, Belgium
University Clinical Center of the Republic of Srpska
Banja Luka, Bosnia and Herzegovina
Clinic of Oncology, University Clinical Center Sarajevo
Sarajevo, Bosnia and Herzegovina
Instituto Nacional de Cancer - INCa; Pesquisa Clinica
Rio de Janeiro, Rio de Janeiro, Brazil
Hospital das Clinicas - UFRGS
Porto Alegre, Rio Grande do Sul, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, Brazil
Hospital A. C. Camargo; Oncologia
São Paulo, São Paulo, Brazil
Hospital Sao Jose
São Paulo, São Paulo, Brazil
District Oncology Dispensary; Department for Oncology and Dermatology
Plovdiv, Bulgaria
National Specialized Hospital for Active Oncology Treatment; Dermatology Clinic
Sofia, Bulgaria
Cross Cancer Institute ; Dept of Medical Oncology
Edmonton, Alberta, Canada
Lion'S Gate Hospital
North Vancouver, British Columbia, Canada
British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre
Vancouver, British Columbia, Canada
St. Boniface General Hospital; Medicine
Winnipeg, Manitoba, Canada
Showing 40 of 280 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.